| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Departments of
*
Surgery and
Microbiology and Immunology, University of Maryland Medical School, Baltimore, MD 21201; and
Experimental Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892
CD103 is an integrin with specificity for the epithelial cell-specific ligand, E-cadherin. Recent studies indicate that CD103 expression endows peripheral CD8 cells with a unique capacity to access the epithelial compartments of organ allografts. In the present study we used a nonvascularized mouse renal allograft model to 1) define the mechanisms regulating CD103 expression by graft-infiltrating CD8 effector populations, and 2) identify the cellular compartments in which this occurs. We report that CD8 cells responding to donor alloantigens in host lymphoid compartments do not initially express CD103, but dramatically up-regulate CD103 expression to high levels subsequent to migration to the graft site. CD103+CD8+ cells that infiltrated renal allografts exhibited a classic effector phenotype and were selectively localized to the graft site. CD8 cells expressing low levels of CD103 were also present in lymphoid compartments, but three-color analyses revealed that these are almost exclusively of naive phenotype. Adoptive transfer studies using TCR-transgenic CD8 cells demonstrated that donor-specific CD8 cells rapidly and uniformly up-regulate CD103 expression following entry into the graft site. Donor-specific CD8 cells expressing a dominant negative TGF-
receptor were highly deficient in CD103 expression following migration to the graft, thereby implicating TGF- activity as a dominant controlling factor. The relevance of these data to conventional (vascularized) renal transplantation is confirmed. These data support a model in which TGF- activity present locally at the graft site plays a critical role in regulating CD103 expression, and hence the epitheliotropism, of CD8 effector populations that infiltrate renal allografts.
This article has been cited by other articles:
|
|
 |
|
  S. Schlickum, H. Sennefelder, M. Friedrich, G. Harms, M. J. Lohse, P. Kilshaw, and M. P. Schon Integrin {alpha}E(CD103){beta}7 influences cellular shape and motility in a ligand-dependent fashion Blood, August 1, 2008; 112(3): 619 - 625. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Masson, T. Calzascia, W. Di Berardino-Besson, N. de Tribolet, P.-Y. Dietrich, and P. R. Walker Brain Microenvironment Promotes the Final Functional Maturation of Tumor-Specific Effector CD8+ T Cells J. Immunol., July 15, 2007; 179(2): 845 - 853. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. L. Floc'h, A. Jalil, I. Vergnon, B. L. M. Chansac, V. Lazar, G. Bismuth, S. Chouaib, and F. Mami-Chouaib {alpha}E{beta}7 integrin interaction with E-cadherin promotes antitumor CTL activity by triggering lytic granule polarization and exocytosis J. Exp. Med., March 19, 2007; 204(3): 559 - 570. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Uss, A. T. Rowshani, B. Hooibrink, N. M. Lardy, R. A. W. van Lier, and I. J. M. ten Berge CD103 Is a Marker for Alloantigen-Induced Regulatory CD8+ T Cells. J. Immunol., September 1, 2006; 177(5): 2775 - 2783. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Keino, S. Masli, S. Sasaki, J. W. Streilein, and J. Stein-Streilein CD8+ T Regulatory Cells Use a Novel Genetic Program that Includes CD103 to Suppress Th1 Immunity in Eye-Derived Tolerance. Invest. Ophthalmol. Vis. Sci., April 1, 2006; 47(4): 1533 - 1542. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. E. Lunsford, M. A. Koester, A. M. Eiring, P. H. Horne, D. Gao, and G. L. Bumgardner Targeting LFA-1 and CD154 Suppresses the In Vivo Activation and Development of Cytolytic (CD4-Independent) CD8+ T Cells J. Immunol., December 15, 2005; 175(12): 7855 - 7866. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Woodberry, T. J. Suscovich, L. M. Henry, M. August, M. T. Waring, A. Kaur, C. Hess, J. L. Kutok, J. C. Aster, F. Wang, et al. {alpha}E{beta}7 (CD103) Expression Identifies a Highly Active, Tonsil-Resident Effector-Memory CTL Population J. Immunol., October 1, 2005; 175(7): 4355 - 4362. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Yuan, R. El-Asady, K. Liu, D. Wang, C. B. Drachenberg, and G. A. Hadley Critical Role for CD103+CD8+ Effectors in Promoting Tubular Injury following Allogeneic Renal Transplantation J. Immunol., September 1, 2005; 175(5): 2868 - 2879. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Grueter, M. Petter, T. Egawa, K. Laule-Kilian, C. J. Aldrian, A. Wuerch, Y. Ludwig, H. Fukuyama, H. Wardemann, R. Waldschuetz, et al. Runx3 Regulates Integrin {alpha}E/CD103 and CD4 Expression during Development of CD4-/CD8+ T Cells J. Immunol., August 1, 2005; 175(3): 1694 - 1705. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. El-Asady, R. Yuan, K. Liu, D. Wang, R. E. Gress, P. J. Lucas, C. B. Drachenberg, and G. A. Hadley TGF-{beta}-dependent CD103 expression by CD8+ T cells promotes selective destruction of the host intestinal epithelium during graft-versus-host disease J. Exp. Med., May 16, 2005; 201(10): 1647 - 1657. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Suffia*, S. K. Reckling*, G. Salay*, and Y. Belkaid* A Role for CD103 in the Retention of CD4+CD25+ Treg and Control of Leishmania major Infection J. Immunol., May 1, 2005; 174(9): 5444 - 5455. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. L. Staton, B. Johnston, E. C. Butcher, and D. J. Campbell Murine CD8+ Recent Thymic Emigrants are {alpha}E Integrin-Positive and CC Chemokine Ligand 25 Responsive J. Immunol., June 15, 2004; 172(12): 7282 - 7288. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
